Since the initial descriptions of CD4 T cell depletion as a critical factor associated with progression to AIDS, our understanding of immune dysfunction in HIV infection has dramatically evolved. Over the past decade, in particular, technical progress and conceptual advances have allowed the exploration of a wide array of qualitative and functional changes that occur in multiple cell types and several compartments of the body. The realization that chronic immune activation is a major driving force in disease progression and associated with clinical complications even in patients on antiretroviral therapy has fostered progress in clarifying the complex interplay between the virus and the infected host. Unfortunately, although improvement in antiretroviral therapy has been dramatic since the mid 1990s, the better understanding of immune impairment has yet to result in therapeutic interventions that efficiently complement antiretroviral therapy (ART) or improve the efficacy of HIV vaccine candidates. However, recent progress in other fields of medicine gives reasons for optimism. In particular, new immunotherapies have shown dramatic results in treatment of several autoimmune diseases and previously refractory types of cancer, with, in many cases, very good tolerance by the patients. The efficacy of these clinical interventions suggests that in the field of chronic infectious diseases -in particular HIV -the knowledge gained in animal models and human studies will translate into better patient care and preventive strategies.
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In this issue, a series of reviews cover new progress in the understanding of immune cell dysfunction in HIV infection. Several themes are also addressed in the perspective of studies of other chronic viral infections in humans, nonhuman primates or mice. The importance of both cellextrinsic factors provided by the altered microenvironment of HIV infection and cell-intrinsic factors, including genetic exhaustion programs, is addressed. These articles provide an overview of mechanisms that affect function of both the innate and adaptive immunity. Our understanding of the complexity of immune cell dysfunction -here defined as exhaustion in a broad sense -has expanded dramatically in recent years. There are reasons to be optimistic and to hope that the time is near when this knowledge will be translated into new therapeutic approaches to complement ART and into better patient care.
